• Vaccine Name: rSPV/H3-2A-H1
• Target Pathogen: Influenza virus
• Target Disease: Influenza (flu)
• Vaccine Ontology ID: VO_0004755
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Vector:
  • Vector name:
  • VO vector ID: VO_0001106
• Preparation: Recombinant swinepox virus (rSPV/H3-2A-H1) co-expressing hemagglutinin (HA1) of SIV subtypes H1N1 and H3N2 (Xu et al., 2013).
• Immunization Route: Intramuscular injection (i.m.)

Guinea pig Response

• Vaccination Protocol: Guinea pigs in groups 1 and 2 were inoculated in all four legs with 0.4 × 10^7.0 TCID50 of rSPV/H3-2A-H1 in 0.4 ml EMEM. In groups 3 and 4, each guinea pig was inoculated with 0.4 × 10^7.0 TCID50 wtSPV in 0.4 ml EMEM. In groups 5 and 6, each guinea pig was inoculated with 0.4 ml of EMEM. All inoculations were administered intramuscularly twice at 1 and 21 days post-inoculation (dpi) (Xu et al., 2013).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: At 35 dpi, the guinea pigs in groups 1, 3 and 5 were challenged by nasal inoculation with 0.4 × 10^5.0 TCID50 SIV H1N1, and those in groups 2, 4 and 6 were challenged with 0.4 × 10^5.0 TCID50 SIV H3N2 (Xu et al., 2013).
• Efficacy: Complete protection of guinea pigs against SIV H1N1 or H3N2 challenge was observed. No SIV shedding was detected from guinea pigs vaccinated with rSPV/H3-2A-H1 after challenge. Most importantly, the guinea pigs immunized with rSPV/H3-2A-H1 did not show gross and micrographic lung lesions (Xu et al., 2013).